Nucleic acid nanoparticles, or NANPs, rationally designed to communicate with the human
immune system, can offer innovative therapeutic strategies to overcome the limitations of …

Nucleic acid nanoparticles (NANPs) represent a highly versatile molecular platform for the
targeted delivery of various therapeutics. However, despite their promise, further clinical …

912Nucleic acid nanoparticles (NANPs) have evolved as a new class of therapeutics with
the potential to detect and treat diseases. Despite tremendous advancements in NANP …

The relatively straightforward methods of designing and assembling various functional
nucleic acids into nanoparticles offer advantages for applications in diverse diagnostic and …

Infusion reactions (IRs) create a translational hurdle for many novel therapeutics, including
those utilizing nanotechnology. Nucleic acid nanoparticles (NANPs) are a novel class of …

This protocol assesses proinflammatory properties of nucleic acid nanoparticles (NANPs)
using a validated preclinical model, peripheral blood mononuclear cells (PBMCs), that is …

1046The unknown immune stimulation by nucleic acid nanoparticles (NANPs) has become
one of the major impediments to a broad spectrum of clinical developments of this novel …

Nucleic acids are programmable and biocompatible polymers that have beneficial uses in
nanotechnology with broad applications in biosensing and therapeutics. In some cases …

Vaccines harness the inherent properties of the immune system to prevent diseases or treat
existing ones. Continuous efforts have been devoted to both gaining a mechanistic …

Introduction: Clinical translation of nucleic acid-based therapeutics (NATs) is hampered by
assorted challenges in immunotoxicity, hematotoxicity, pharmacokinetics, toxicology and …